Toleranzia AB - Product Pipeline Review - 2015

Toleranzia AB - Product Pipeline Review - 2015


Global Markets Direct’s, ‘Toleranzia AB - Product Pipeline Review - 2015’, provides an overview of the Toleranzia AB’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Toleranzia AB’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


  • The report provides brief overview of Toleranzia AB including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Toleranzia AB’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Toleranzia AB’s pipeline products
Reasons to buy
  • Evaluate Toleranzia AB’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Toleranzia AB in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Toleranzia AB’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Toleranzia AB and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Toleranzia AB
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Toleranzia AB and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Toleranzia AB Snapshot
Toleranzia AB Overview
Key Information
Key Facts
Toleranzia AB - Research and Development Overview
Key Therapeutic Areas
Toleranzia AB - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Toleranzia AB - Pipeline Products Glance
Toleranzia AB - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Toleranzia AB - Drug Profiles
Recombinant Protein for Allergy
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein for Autoimmune Orphan Indications
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein for Multiple Sclerosis
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein for Myasthenia Gravis
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein for Rheumatoid Arthritis
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein for Sjogren's Syndrome
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein for Type 1 Diabetes
Product Description
Mechanism of Action
R&D Progress
Toleranzia AB - Pipeline Analysis
Toleranzia AB - Pipeline Products by Route of Administration
Toleranzia AB - Pipeline Products by Molecule Type
Toleranzia AB - Locations And Subsidiaries
Head Office
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
List of Tables
Toleranzia AB, Key Information
Toleranzia AB, Key Facts
Toleranzia AB - Pipeline by Indication, 2015
Toleranzia AB - Pipeline by Stage of Development, 2015
Toleranzia AB - Monotherapy Products in Pipeline, 2015
Toleranzia AB - Preclinical, 2015
Toleranzia AB - Pipeline by Route of Administration, 2015
Toleranzia AB - Pipeline by Molecule Type, 2015
List of Figures
Toleranzia AB - Pipeline by Top 10 Indication, 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook